Company / Cash & Equivalents
Korro Bio, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$21.8M
FY2025
5-year range
$21.8M / $220.3M
FY2021-FY2025
Trend
-40.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 4 consecutive years, from $220M in FY2020 to $22M in FY2025.
Based on SEC 10-K filings.
$22M in FY2025 with a 5-year CAGR of -37.0%.
Declined from $52M to $22M over the past 3 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -25.1%
- 5-Year CAGR
- -37.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- Korro Bio, Inc.'s cash & equivalents has declined for 4 consecutive years.
- 5-year CAGR of -37.0%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 40.4% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $21.8M | -40.4% |
| FY2024 | $36.6M | -29.6% |
| FY2022 | $52.0M | -34.8% |
| FY2021 | $79.6M | -63.9% |
| FY2020 | $220.3M | +10.1% |
| FY2019 | $200.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026